Asset Details
Do you wish to reserve the book?
Epithelial growth factor receptor status in primary and recurrent ovarian cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Epithelial growth factor receptor status in primary and recurrent ovarian cancer
Do you wish to request the book?
Epithelial growth factor receptor status in primary and recurrent ovarian cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Epithelial growth factor receptor status in primary and recurrent ovarian cancer
2006
Overview
Success of epidermal growth factor receptor (EGFR) targeting agents in different cancer types is related to EGFR gene mutations and/or copy number gains. We investigated the EGFR gene status and protein expression by DNA mutational analysis, fluorescence in situ hybridization (FISH), and immunohistochemistry in tumor tissues from 80 patients with primary and corresponding recurrent ovarian serous carcinomas. The patients were classified into six groups with ascending EGFR gene copy numbers. EGFR amplification and high polysomy (FISH+) was present in a significant fraction of the primary (20%) and recurrent (22%) ovarian carcinomas. On mutational analysis, only one tumor with a silent EGFR mutation was observed, and this was the only carcinoma with high-level amplification. EGFR protein immunoexpression was seen in 28% of primary and 33% of recurrent carcinomas and correlated to amplification in the primary tumors (P=0.003). In recurrent carcinoma, moderate and strong EGFR expression was associated with amplification (P=0.034). These molecular events potentially have impact on the responsiveness to EGFR targeting agents in ovarian cancer.
Publisher
Elsevier Inc,Nature Publishing Group US,Elsevier Limited
Subject
/ Aged
/ Cystadenocarcinoma, Serous - genetics
/ Cystadenocarcinoma, Serous - metabolism
/ Cystadenocarcinoma, Serous - pathology
/ epidermal growth factor receptor
/ Female
/ fluorescence in situ hybridization
/ Humans
/ In Situ Hybridization, Fluorescence
/ Medicine
/ Mutation
/ Ovarian Neoplasms - genetics
/ Ovarian Neoplasms - metabolism
